Pharming Group N.V.

Pharming Group N.V. is a biopharmaceutical company that develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases globally. Its lead product is RUCONEST, a recombinant C1 esterase inhibitor used to treat acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE). The company also offers Joenja (leniolisib), an oral small molecule PI3Kδ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. Additionally, Pharming has a development collaboration and license agreement with Novartis.

Pharming Group N.V. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol PHAR. Its securities trade in US dollars (USD). The company is headquartered in Leiden, the Netherlands, and its stock is accessible to investors in the US region.

Pharming Group N.V. operates in the Healthcare sector and specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on developing and commercializing therapies for rare diseases, leveraging recombinant protein technology and precision medicine approaches.

Pharming Group N.V. is headquartered in Leiden, the Netherlands. The company serves global markets, with its products targeting patients with rare diseases worldwide. Its lead product, RUCONEST, is used for hereditary angioedema, and Joenja addresses activated phosphoinositide 3-kinase delta syndrome, both of which are distributed internationally.

Pharming Group N.V.'s main products include RUCONEST, a recombinant C1 esterase inhibitor for treating acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE), and Joenja (leniolisib), an oral small molecule PI3Kδ inhibitor for treating activated phosphoinositide 3-kinase delta syndrome. The company also has a development collaboration and license agreement with Novartis, though specific details of this collaboration are not provided.